

***Fiscal Year 2020 Epilepsy Research Program
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-20-ERP-IDA</p>	<p>Level I: Investigators at or above the level of postdoctoral fellow (e.g., research associates, fellows, medical residents, or equivalent) but below the level of Assistant Professor (or equivalent) at the time of the application deadline.</p> <ul style="list-style-type: none"> • Mentor(s) required. <p>Level II: The Principal Investigator (PI) must be an independent investigator at or above the level of Assistant Professor (or equivalent).</p>	<p>Intent: To solicit novel, innovative research to understand the magnitude and underlying mechanisms of post-traumatic epilepsy (PTE).</p> <ul style="list-style-type: none"> • Level I: Applicant can be from any field or discipline and must write the project narrative and other application components, with appropriate guidance from the Mentor(s). The Mentor(s) must possess qualifications, background, and experience in PTE research. • Level II is intended to support a more mature, hypothesis-driven research project. Applicants can be from any field or discipline. <p>Applicants should select one of the Focus Areas below:</p> <ul style="list-style-type: none"> • Innovative Research • Markers and Mechanisms • Epidemiology • Longitudinal Studies <p>While not required, applications to either Funding Level I or II are encouraged to provide relevant preliminary data.</p> <p>Clinical pharmacologic trials are specifically discouraged.</p>	<p>Level I:</p> <ul style="list-style-type: none"> • Maximum funding of \$300,000 for direct costs (plus indirect costs). • Maximum period of performance is 3 years. • Indirect costs may be proposed in accordance with the institution’s rate agreement. <p>Level II:</p> <ul style="list-style-type: none"> • Maximum funding of \$500,000 for direct costs (plus indirect costs). • Maximum period of performance is 3 years. • Indirect costs may be proposed in accordance with the institution’s rate agreement. 	<p>Pre-Application (Letter of Intent): June 22, 2020 5:00 p.m. Eastern time (ET)</p> <p>Application: July 21, 2020 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Quality of Life Award</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-20-ERP-QOL</p>	<p>Level I: Investigators at or above the level of postdoctoral fellow (e.g., research associates, fellows, medical residents, or equivalent) but below the level of Assistant Professor (or equivalent) at the time of the application deadline.</p> <ul style="list-style-type: none"> Mentor(s) required. <p>Level II: The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).</p>	<p>Intent: To support research that improves the quality of life and care for individuals living with the symptoms of PTE.</p> <ul style="list-style-type: none"> Level I: Applicant can be from any field or discipline and must write the project narrative and other application components, with appropriate guidance from the Mentor(s). The Mentor(s) must possess qualifications, background, and experience in PTE research. Level II is intended to support a more mature, hypothesis-driven research project. Applicants can be from any field or discipline. <p>The following Focus Area must be addressed as part of the application:</p> <ul style="list-style-type: none"> Quality of Life <p>An application that proposes research outside of this Focus Area will be withdrawn.</p> <p>While not required, applications to either Funding Level I or II are encouraged to provide relevant preliminary data.</p> <p>Clinical pharmacologic trials are specifically discouraged.</p> <p>Animal research is specifically discouraged.</p>	<p>Level I:</p> <ul style="list-style-type: none"> Maximum funding of \$300,000 for direct costs (plus indirect costs). Maximum period of performance is 3 years. Indirect costs may be proposed in accordance with the institution's rate agreement. <p>Level II:</p> <ul style="list-style-type: none"> Maximum funding of \$500,000 for direct costs (plus indirect costs). Maximum period of performance is 3 years. Indirect costs may be proposed in accordance with the institution's rate agreement. 	<p>Pre-Application (Letter of Intent):</p> <p>June 22, 2020 5:00 p.m. ET</p> <p>Application:</p> <p>July 21, 2020 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Research Partnership Award:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-20-ERP-RPA</p>	<p>The initiating PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).</p> <p>Each named Co-PI must be at or above the level of assistant professor (or equivalent).</p>	<p>Intent: To create an avenue for collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts.</p> <ul style="list-style-type: none"> Level I is intended to support preclinical or pre-validation research. Level II is intended to support research requiring access to a patient cohort for a prospective study. <p>Applications must include clearly stated plans for interactions between/among the partners. The plans must include communication, decision-making, allocation of resources, coordination of research progress and results, and sharing of data among all investigators and organizations participating in the project.</p> <p>Applicants should select one of the Focus Areas below:</p> <ul style="list-style-type: none"> Markers and Mechanisms Epidemiology Longitudinal Studies <p>Preliminary data to support the feasibility of the research hypothesis (or hypotheses) or objectives are <i>required</i>.</p> <p>Clinical pharmacologic trials are specifically discouraged.</p>	<p>Level I:</p> <ul style="list-style-type: none"> Maximum funding of \$1,300,000 in total costs. Maximum period of performance is 3 years. Indirect costs may be proposed in accordance with the institution’s rate agreement. <p>Level II:</p> <ul style="list-style-type: none"> Maximum funding of \$3,100,000 in total costs Maximum period of performance is 4 years. Indirect costs may be proposed in accordance with the institution’s rate agreement. 	<p>Pre-Application (Letter of Intent):</p> <p>June 22, 2020 5:00 p.m. ET</p> <p>Application:</p> <p>July 21, 2020 11:59 p.m. ET</p>